Biogen: Run Lola Run?

When things go bad for a momentum stock, it gets real ugly real fast. Just look at Biogen (BIIB). At a recent $312.71, the share fell 18.7% in afternoon market action after earlier falling more than 20%. The biotech giant cut its full-year revenue and earnings guidance amid weakening prospects for its blockbuster multiple sclerosis [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.